Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Antony Website

Smitha Antony, Ph.D.

Portait Photo of Smitha Antony
Developmental Therapeutics Branch
Oxidative Signaling and Molecular Therapeutics Group
Staff Scientist
Center for Cancer Research
National Cancer Institute
Building 37, Room 1052
37 Convent Drive
Bethesda, MD 20892


Dr. Smitha Antony is a staff scientist in the Oxidative Signaling and Molecular Therapeutics Section at the National Cancer Institute, NIH. She received her Ph.D. in microbiology and cell biology in 2001 from the Indian Institute of Science. Dr. Antony joined the NCI in 2002 and has made substantial contributions in the discovery and optimization of novel topoisomerase inhibitors, the indenoisoquinolines. Two indenoisoquinoline derivatives are in clinical trials at the NIH with histone γ-H2AX and Top1 levels used as pharmacodynamic biomarkers.

Dr. Antony is the recipient of the Federal Technology Transfer Award and the NCI Certificate of Appreciation for recognition of outstanding contributions to research innovation for her work on human topoisomerase I (Top1) and human tyrosyl DNA phosphodiesterase I (Tdp1) inhibitors and the development and characterization of the NADPH oxidase 5 (NOX5) monoclonal antibody. Dr. Antony has co-authored many publications in the field of DNA damage and repair and holds several patents for inhibitors of DNA topoisomerases.


Reactive oxygen species (ROS) have been implicated in physiological and pathophysiological signaling pathways, including cancer development and progression. Our laboratory focuses on the role of oxidant-mediated signaling in tumor cell proliferation. We are particularly interested in the epithelial NADPH oxidase (NOX) gene family and are focused on three specific areas of research: a) Evaluating the role of the NOX gene family members in tumor cell growth control and angiogenesis; b) Examining the role of members of the NOX family in modulating pro-inflammatory, cytokine-related signal transduction in tumor cells; and c) Developing novel inhibitors of NOX isoforms and evaluating their potential as cancer therapeutic agents.

This page was last updated on 4/21/2014.